Molecular Pharmaceutics
[ASAP] Azide-Locked Prodrug Co-Assembly into Nanoparticles with Indocyanine Green for Chemophotothermal Therapy
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00452
Molecular Pharmaceutics
[ASAP] A Silk-Based Platform to Stabilize Phenylalanine Ammonia-lyase for Orally Administered Enzyme Replacement Therapy
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00512
Molecular Pharmaceutics
[ASAP] Development of <sup>68</sup>Ga-Labeled Hepatitis E Virus Nanoparticles for Targeted Drug Delivery and Diagnostics with PET
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00359
Molecular Pharmaceutics
[ASAP] Impact of the Dicarboxylic Acid Chain Length on Intermolecular Interactions with Lidocaine
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00381
Molecular Pharmaceutics
[ASAP] Strategies for Taste Masking of Orodispersible Dosage Forms: Time, Concentration, and Perception
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00199
Molecular Pharmaceutics
[ASAP] Impact of an Adenosine A<sub>2A</sub> Receptor Agonist and Antagonist on Binding of the Dopamine D<sub>2</sub> Receptor Ligand [<sup>11</sup>C]raclopride in the Rodent Striatum
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00450
Molecular Pharmaceutics
[ASAP] Cubosomal Lipid Formulation for Combination Cancer Treatment: Delivery of a Chemotherapeutic Agent and Complexed α‑Particle Emitter <sup>213</sup>Bi
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00182
Molecular Pharmaceutics
[ASAP] B16F10 Cell Membrane-Based Nanovesicles for Melanoma Therapy Are Superior to Hyaluronic Acid-Modified Nanocarriers
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00212
Molecular Pharmaceutics
[ASAP] Delivery of Small Molecules by Syndiotactic Peptides for Breast Cancer Therapy
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00238
Molecular Pharmaceutics
[ASAP] Experimental and Computational Investigation of Clustering Behavior of Cyclodextrin–Perfluorocarbon Inclusion Complexes as Effective Histotripsy Agents
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00268